Johnson & Johnson's $2.2 billion settlement

• Autores: Curtis C. Verschoor
• Localización: Strategic Finance, ISSN-e 1524-833X, Vol. 96, Nº. 2, 2014, págs. 11-14
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • The article looks at ethics in business management, focusing on the case of drug and consumer goods company Johnson & Johnson, which reached a large settlement agreement in 2013 over civil and criminal charges related to alleged improper marketing practices by its subsidiary Janssen Pharmaceuticals. It notes the charges included paying kickbacks to doctors and promoting the antipsychotic drug Risperdal for off-label, or unapproved, uses. Compliance with ethical business policies is discussed.